Indexed in

License and use

Citations

Cited 6 times in

Cited 4 times in

Cited 2 times in

Cited 7 times in

Altmetrics

Grant support

The authors thank the patients for their consent to participate in the Hepa-C registry. Medical writing assistance was provided by Connect2 CME Ltd, Tunbridge Wells, Kent, UK and was funded by the Spanish Association for the Study of the Liver.

Analysis of institutional authors

Share

Successful Continuation of HCV Treatment After Liver Transplantation

Publicated to:TRANSPLANTATION. 101 (5): 1009-1012 - 2017-01-01 101(5), DOI: 10.1097/TP.0000000000001596

Authors: Fernandez Carrillo, Carlos; Crespo, Gonzalo; de la Revilla, Juan; Castells, Lluis; Buti, Maria; Luis Montero, Jose; Fabrega, Emilio; Fernandez, Inmaculada; Serrano-Millan, Cristina; Hernandez, Victoria; Luis Calleja, Jose; Londono, Maria-Carlota;

Affiliations

Abstract

Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated for HCV before liver transplant (LT) to eliminate the virus before surgery. However, the unpredictability of donor organ availability may limit treatment duration. Interruption of HCV treatment with resumption post-LT is 1 potential solution which has not been investigated widely.Patients from 5 clinical centers included in the large, national, noninterventional Hepa-C registry who started treatment with direct-acting antiviral agents while awaiting LT were identified retrospectively and followed up prospectively. Fifteen patients who had treatment interruptions around LT were identified.The majority of patients (12/15) received interferon-free regimens, most commonly sofosbuvir + daclatasvir (8/12), for a total of 24 weeks (13/15). Treatment was discontinued temporarily for a median of 5 (range, 2-33) days. Fourteen patients completing 12 weeks of follow-up achieved a sustained virological response. One patient who died before week 12 posttreatment achieved a response at posttreatment week 4. Treatment was generally well tolerated. Serious adverse events were recorded in 2 of 15 patients (anaemia in 1 patient; pneumonia in 1 patient); all arose after LT.Resumption of direct-acting antiviral agent therapy after a temporary interruption around LT was highly effective, achieving sustained virological response in all patients who completed 12 weeks of posttreatment follow-up. Treatment was generally well tolerated pretransplantation and posttransplantation, with a low rate of serious adverse events. Such a strategy may offer an important new approach to the treatment of patients awaiting LT which may be assessed in future studies.

Keywords